Anna Fedeli

Via Antonio Canova, 15/E
Bologna, 40138, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

Investigating biochemical markers of Acupuncture's effectiveness in managing climacteric syndrome in breast cancer patients: the FLAIR study.

Investigating biochemical markers of Acupuncture's effectiveness in managing climacteric syndrome in breast cancer patients: the FLAIR study.

Journal: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer

Published: July 29, 2025

Phase II study of liposomal doxorubicin, docetaxel and trastuzumab in combination with metformin as neoadjuvant therapy for HER2-positive breast cancer.

Phase II study of liposomal doxorubicin, docetaxel and trastuzumab in combination with metformin as neoadjuvant therapy for HER2-positive breast cancer.

Journal: Therapeutic advances in medical oncology

Published: September 29, 2020

Exploratory Analysis of 18F-3'-deoxy-3'-fluorothymidine (18F-FLT) PET/CT-Based Radiomics for the Early Evaluation of Response to Neoadjuvant Chemotherapy in Patients With Locally Advanced Breast Cancer.

Exploratory Analysis of 18F-3'-deoxy-3'-fluorothymidine (18F-FLT) PET/CT-Based Radiomics for the Early Evaluation of Response to Neoadjuvant Chemotherapy in Patients With Locally Advanced Breast Cancer.

Journal: Frontiers in oncology

Published: August 31, 2020

Ki67 and PR in Patients Treated with CDK4/6 Inhibitors: A Real-World Experience.

Ki67 and PR in Patients Treated with CDK4/6 Inhibitors: A Real-World Experience.

Journal: Diagnostics (Basel, Switzerland)

Published: July 03, 2020

Androgen receptor in advanced breast cancer: is it useful to predict the efficacy of anti-estrogen therapy?

Androgen receptor in advanced breast cancer: is it useful to predict the efficacy of anti-estrogen therapy?

Journal: BMC cancer

Published: November 29, 2017

Sorafenib for the treatment of breast cancer.

Sorafenib for the treatment of breast cancer.

Journal: Expert opinion on pharmacotherapy

Published: March 25, 2017

Phase Ib dose-finding trial of lapatinib plus pegylated liposomal doxorubicin in advanced HER2-positive breast cancer.

Phase Ib dose-finding trial of lapatinib plus pegylated liposomal doxorubicin in advanced HER2-positive breast cancer.

Journal: Cancer chemotherapy and pharmacology

Published: October 13, 2016

Androgen receptor signaling pathways as a target for breast cancer treatment.

Androgen receptor signaling pathways as a target for breast cancer treatment.

Journal: Endocrine-related cancer

Published: August 11, 2016

Pharmacokinetics, pharmacodynamics and clinical efficacy of pertuzumab in breast cancer therapy.

Pharmacokinetics, pharmacodynamics and clinical efficacy of pertuzumab in breast cancer therapy.

Journal: Expert opinion on drug metabolism & toxicology

Published: August 27, 2015

Efficacy of endocrine therapy in relation to progesterone receptor and Ki67 expression in advanced breast cancer.

Efficacy of endocrine therapy in relation to progesterone receptor and Ki67 expression in advanced breast cancer.

Journal: Breast cancer research and treatment

Published: December 12, 2014

Trastuzumab-induced cardiotoxicity in early breast cancer patients: a retrospective study of possible risk and protective factors.

Trastuzumab-induced cardiotoxicity in early breast cancer patients: a retrospective study of possible risk and protective factors.

Journal: Heart (British Cardiac Society)

Published: January 26, 2013

Showing 1-11 of 11

Last Updated: 09/26/2026